Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment
Open Access
- 6 June 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0302269
Abstract
Intravenous thrombolysis with a recombinant tissue plasminogen activator (rt-PA) is the first-line treatment of acute ischemic stroke. However, successful recanalization is relatively low and the underlying processes are not completely understood. The goal was to provide insights into clinically important factors potentially limiting rt-PA efficacy such as clot size, rt-PA concentration, clot age and also rt-PA in combination with heparin anticoagulant. We established a static in vitro thrombolytic model based on red blood cell (RBC) dominant clots prepared using spontaneous clotting from the blood of healthy donors. Thrombolysis was determined by clot mass loss and by RBC release. The rt-PA became increasingly less efficient for clots larger than 50 μl at a clinically relevant concentration of 1.3 mg/l. A tenfold decrease or increase in concentration induced only a 2-fold decrease or increase in clot degradation. Clot age did not affect rt-PA-induced thrombolysis but 2-hours-old clots were degraded more readily due to higher activity of spontaneous thrombolysis, as compared to 5-hours-old clots. Finally, heparin (50 and 100 IU/ml) did not influence the rt-PA-induced thrombolysis. Our study provided in vitro evidence for a clot size threshold: clots larger than 50 μl are hard to degrade by rt-PA. Increasing rt-PA concentration provided limited thrombolytic efficacy improvement, whereas heparin addition had no effect. However, the higher susceptibility of younger clots to thrombolysis may prompt a shortened time from the onset of stroke to rt-PA treatment.Keywords
Funding Information
- European Regional Development Fund (CZ.02.1.01/0.0/0.0/16_026/0008451)
- Masarykova Univerzita (MUNI/A/1301/2022)
- Brno City Municipality (Ph.D Talent 2019)
This publication has 42 references indexed in Scilit:
- High Rate of Complete Recanalization and Dramatic Clinical Recovery During tPA Infusion When Continuously Monitored With 2-MHz Transcranial Doppler MonitoringStroke, 2000
- PROACT: A Phase II Randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute Middle Cerebral Artery StrokeStroke, 1998
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.Journal of Clinical Investigation, 1995
- Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase)The American Journal of Cardiology, 1994
- “Plasminogen steal” and clot lysisJACC, 1992
- Marked potentiation of the plasminogenolytic activitiy of pro-urokinase by unfractionated heparin and a low molecular-weight heparinThrombosis Research, 1988
- Effect of a Selective Thrombin Inhibitor MCI-9038 on Fibrinolysis In Vitro and In VivoThrombosis and Haemostasis, 1986
- Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogenBiochemistry, 1986
- Study on the mechanism of action of heparin and related substances on the fibrinolytic system: Relationsship between plasminogen activators and heparinThrombosis Research, 1986